Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).

@article{Faire1996SecondaryPP,
  title={Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).},
  author={Ulf H de Faire and Christina Ericsson and Lars Grip and J. W. Nilsson and Bertil Svane and Anders Hamsten},
  journal={European heart journal},
  year={1996},
  volume={17 Suppl F},
  pages={37-42}
}
Current experience from coronary angiographic trials using different treatment regimens such as lifestyle changes, resins, nicotinic acid and statins, shows that progression of atheroma can be retarded, and that regression can sometimes be induced, by a marked lowering of LDL-cholesterol. Young post-myocardial infarction patients, however, usually exhibit a multiplicity of metabolic risk factors with dyslipidaemias, predominantly hypertriglyceridaemia, and disturbances of glucose-insulin… CONTINUE READING